文献速递临床试验与 GCP医学人工智能与信息学

利用肺部病灶PET/CT影像对结核患者进行缩短药物治疗疗程的临床测试

Clinical testing of drug treatment shortening in patients with TB using PET/CT imaging of lung lesions.
PubMed 文献 · Sci Transl Med · 2026-01-07

PredictTB是一项在南非和中国开展的前瞻性随机对照非劣效性试验,纳入704例新诊断药物敏感肺结核患者,按FDG PET/CT影像特征分层。病灶范围较小者(n=273)在第16周随机分配为4个月或6个月化疗,因中期分析显示4个月组复发风险更高而提前终止:4个月组141例中17例(12.1%)出现结核相关不良结局,6个月组132例中仅2例(1.5%)。

要点

  • 病灶范围较小者4个月化疗的结核相关不良结局为12.1%(17/141),6个月组为1.5%(2/132),试验因4个月组复发风险更高而提前终止。
  • 第16周总肺空洞容积和病灶糖酵解与不良结局风险相关。
  • 结核复发时PET/CT显示细菌学复发主要发生在基线时已存在的活动性空洞中。

核心结论

  • 在病灶范围较小的药物敏感肺结核患者中,4个月化疗的结核相关不良结局风险高于6个月化疗,试验因中期分析显示4个月组复发风险更高而提前终止。

研究设计与样本

  • 前瞻性、随机、对照非劣效性试验(PredictTB),在南非和中国开展,纳入704例新诊断药物敏感肺结核患者。
  • 根据FDG PET/CT影像评估的病变特征进行分层,病灶范围较小者(n=273)在第16周随机分配为完成4个月或继续6个月治疗。
  • 非随机组纳入病灶范围较大的患者(n=248)。

主要发现

  • 4个月化疗组141例中17例(12.1%)出现结核相关不良结局,6个月化疗组132例中仅2例(1.5%)。
  • 非随机组(病灶范围较大)248例中仅8例(3.2%)出现不良结局。
  • 第16周总肺空洞容积和病灶糖酵解与不良结局风险相关。
  • 结核复发时PET/CT显示细菌学复发主要发生在基线时已存在的活动性空洞中。
  • 后续对系列PET/CT扫描的事后自动分割结合机器学习可对参与者的复发可能性进行分类。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Six months of drug treatment is standard of care for drug-sensitive pulmonary tuberculosis (TB). Understanding the factors determining the length of treatment required for durable cure would allow individualization of treatment durations. We conducted a prospective, randomized, controlled noninferiority trial (PredictTB) of 4 versus 6 months of chemotherapy in patients with pulmonary TB in South Africa and China. Seven hundred and four participants with newly diagnosed, drug-sensitive TB were enrolled and stratified on the basis of radiographic disease characteristics assessed by FDG PET/CT imaging. Participants with less extensive disease (n = 273) were randomly assigned at week 16 to complete therapy after 4 months or continue receiving treatment for 6 months. This study was stopped early after an interim analysis revealed that patients assigned to the 4-month treatment arm had a higher risk of relapse. Among participants who received 4 months of chemotherapy, 17 of 141 (12.1%) experienced TB-specific unfavorable outcomes compared with only 2 of 132 (1.5%) who completed 6 months of treatment. In the nonrandomized arm that included participants with more extensive disease, only 8 of 248 (3.2%) experienced unfavorable outcomes. Total lung cavity volume and lesion glycolysis at week 16 were associated with the risk of unfavorable outcomes. PET/CT imaging at TB recurrence showed that bacteriological relapses predominantly occurred in active cavities originally present at baseline. Subsequent post hoc automated segmentation of serial PET/CT scans combined with machine learning enabled the classification of participants according to their likelihood of relapse.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Malherbe ST, Chen RY, Yu X, et al. Clinical testing of drug treatment shortening in patients with TB using PET/CT imaging of lung lesions. Sci Transl Med. 2026. PMID: 41499522. doi:10.1126/scitranslmed.adt5626

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。